1Jacoba K,Shoemaker C,Rudersdorf R,et al.Isolation and characterization of genomic and cDNA clones of human erythropoietin[J].NaIure,1985,313(28):806-810.
2hi PH.Everett R,Wang FF,et al.Structural characterization of human erythropoietin[J].J Biol Chem,1986,261(7):3118—3121.
3Davis JM,Arakawa T,Strickland TW,et al.Characterization of recombinant human erythropoietin produced in Chinese hamster ovary cells[J].Biochemistry,1987,26(9):2633—2638.
4Choi D,Kim M,Park J.Erythropoietin:physico-and biochemical analysis[J].J Chromatogr B Biomed Appl,1996,687(1):189—199.
5Bahlmann FH.de Groot K,Hermann H,et al.Erythropoletln:is it more than correcting anaemia?[J].Nephrol Dial Transplant,2004,19(1):20-22.
6Segal GM.The progression of renal disease[J].Kidney Int,1988,33(5):983-986.
7Cody J,Daly C,Campbell M.Recombinant human erythropoietion for chronic renal failure anaemia in Pre—dialysis patients[J].Cochrane Database Syst Rev,2001,(4):CD003266.
8Malvinder SP.Chronic renal disease[J].Br Med J,2002,325(7355):85.
9Levin A.Epoetin therapy in chronic kidney disease:cardiovascular benefits[M].Erythropoiesis:New Dimensions in the treatment of anaemia,2001.41—46.
10Portoles J.The beneficial effects of intervention in early renal disease[J].Nep DiaTra,2001,16[Suppl 2]:12-15.
